GLEN.NS

GLEN.NS has a debt-to-equity ratio of 0.28, indicating a relatively conservative capital structure with a lower reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.56, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess. However, the company's operating cash flow is negative at -8.28 billion INR, which may raise concerns about its ability to fund operations from core business activities. Free cash flow, on the other hand, is positive at 7.12 billion INR, indicating that the company is generating cash after capital expenditures. In terms of profitability, GLEN.NS has a return on equity (ROE) of 11.83% and a return on assets (ROA) of 6.52%. These figures suggest that the company is generating a reasonable return for its shareholders and effectively utilizing its assets to generate profit. However, a direct comparison to industry medians is necessary to fully assess its performance relative to peers. GLEN.NS operates in a single business segment focused on pharmaceuticals, with no disclosed geographic revenue concentration data available in the provided information. This lack of diversification may expose the company to specific market risks, particularly in its primary operating region. The company's growth trajectory is not explicitly detailed in the provided data, but its revenue of 133.22 billion INR and net income of 10.47 billion INR suggest a stable financial position. Analysts have provided a mean price target of 2,236.27 INR and a median price target of 2,350.00 INR, indicating a generally positive outlook. The risk assessment for GLEN.NS indicates a low potential for dilution, with a dilution risk score of low. However, the company's negative net cash position after subtracting total debt is a key flag that may impact its financial flexibility. The company has not disclosed any recent events or filings that would significantly alter its risk profile. Recent investor relations observations show a mean recommendation of 1.89, which is slightly above the "strong buy" threshold, with 5 strong-buy ratings, 2 buy ratings, and 1 hold rating. This suggests that analysts are generally optimistic about the company's prospects, although there is some variation in their recommendations.